Author: Ryan Allway

EDMONTON, April 2, 2019 /PRNewswire/ – Aurora Cannabis Inc. (“Aurora” or the “Company”) (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that it has filed a preliminary short form base shelf prospectus (the “Shelf Prospectus”) with the securities regulators in each province of Canada, except for the Province of Quebec, and a corresponding shelf registration statement on Form F‐10 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”).

“Although we have no immediate intention of drawing capital against this Shelf Prospectus, we have introduced this option as a prudent and long-term strategic measure to provide us with flexibility in access to growth capital, if or when required, to continue executing on our global expansion and partnering strategy,” said Michael Singer, Executive Chairman. “With our recent listing on the NYSE, our successful financing in January 2019 led by U.S. institutional investors, and as we work with Nelson Peltz to explore potential partnership opportunities, this filing is a natural evolution for our company as we rapidly mature into a global and profitable organization.”

The Shelf Prospectus and Registration Statement, when made final or effective, will allow the Company to make offerings of common shares, debt securities, subscription receipts, units, warrants or any combination thereof of up to US$750 million during the 25 month period that the Shelf Prospectus is effective. Should the Company decide to offer securities during this period,  the specific terms, including the use of proceeds from any offering, will be set forth in a related prospectus supplement to the Shelf Prospectus, which will be filed with the applicable Canadian securities regulatory authorities and the SEC.

The Company is also considering the use of the Shelf Prospectus and subsequent prospectus supplement to allow for an “at the market distribution” in accordance with applicable securities laws.  An at-the-market distribution provides for securities to be sold by registered dealers on behalf of the Company through the stock exchange at prevailing market prices at the time of sale.  Currently, no agreement has been entered into for an at-the-market distribution.

A copy of the Shelf Prospectus can be found on SEDAR at www.sedar.com and a copy of the Registration Statement can be found on EDGAR at www.sec.gov.

The Registration Statement has been filed with the SEC but has not yet become effective. No securities may be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.

About Aurora 

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora’s facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland have achieved this level of certification.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 16 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs and Whistler – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ) and High Tide Inc. (CSE:HITI).

Aurora’s Common Shares trade on the NYSE and TSX under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.com

Terry Booth, CEO
Aurora Cannabis Inc.

Forward looking statements 

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur and include, but are not to, statements regarding the filing and effectiveness of the final Shelf Prospectus and Registration Statement, the filing and effectiveness of any potential prospectus supplement; the amount and terms of any securities to be offered, and anticipated timing of any financing under the final Shelf Prospectus and Registration Statement. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. including but not limited to, the timing and filing of the final Shelf Prospectus; the potential offering of any securities by the Company; uncertainty with respect to the completion of any future offering; the ability to obtain applicable regulatory approval for any contemplated offerings; the ability of the Company to negotiate and complete future funding transactions, as well as the risks identified under the heading Risk Factors in our Annual Information Form for the fiscal year ended June 30, 2018.  The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Aurora Cannabis Inc.

Related Links

https://auroramj.com/

MONCTON, NB, April 3, 2019 /CNW/ – Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis is pleased to announce the release of a cross-platform patient-focused mobile application (the “Organigram Mobile App” or the “Application”).

The Application was designed to offer patients greater convenience in optimizing their medication regimen and stay up-to-date on products, programs and Company news. Through this new Application, registered patients are able to:

• Order medical cannabis products and accessories
• Manage their patient profile
• View past orders and order limits
• Read the latest Organigram news and press releases
• Communicate with Client Care representatives

“When it comes to managing their medication, patients have indicated to us that convenience and ease are important to them. This new tool gives patients greater ease of control over their wellness plans,” says Organigram CEO Greg Engel.

The Application was developed following a survey of cannabis patients, specifically, their communication preferences and aptitudes to leverage technology. The Organigram Mobile App was created as a direct result of feedback, which suggests cannabis patients are more likely to purchase medication and communicate with licensed producers through a specific application, rather than a web-based browser. The Company continues to explore how to develop tech-based solutions to serve medical and adult recreational consumers.

Prior to October 17, 2018, Organigram reaffirmed its commitment to medical patients by implementing measures to ensure patient care remains a top priority. The Organigram Mobile App adds to recent patient-first actions, including covering the cost of the federal excise tax on medical products, lowering the cost of cannabis oils and ensuring uninterrupted access to a variety of product formats.

“We want our patients to know that in this post-adult recreational world, Organigram is committed to supporting them. It is our hope that this tool makes medical cannabis even more accessible to our patients who prefer a mobile tool,” Engel says.

The app is available free-of-charge from the Organigram website, available for both iOS and Android devices at organigram.ca/app. The Organigram Mobile App is not currently available through the Apple App Store or Google Play store.

About Organigram Holdings Inc. 

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors, including changes impacting demand and technology that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We seek safe harbor.

SOURCE OrganiGram

For further information: For Investor Relations enquiries, please contact: Amy Schwalm, Vice President, Investor Relations, Amy.Schwalm@organigram.ca; For Media enquiries, please contact: Ray Gracewood, Chief Commercial Officer, rgracewood@organigram.ca, (506) 645-1653

Related Links

http://www.organigram.ca

VANCOUVER, British Columbia, April 03, 2019 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX:EMHTF) has signed a letter of intent to supply cannabis to the Société Québécoise du Cannabis (SQDC), Quebec’s sole legal distributor of recreational cannabis. Under the agreement, Emerald will supply cannabis to the SQDC from its Québec-based Saint-Eustache facility, Verdélite, as well as from its 50%-owned joint venture, Pure Sunfarms, in Delta, BC. Emerald will fulfill its first supply order in Q2 2019.

“Québec’s population of 8.4 million is a sizable market and we are pleased to be able to offer locally-grown, quality cannabis products to the adult-use consumers throughout the province,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “Verdélite is now near completion of the build-out of its 88,000 square foot indoor cultivation facility and has been scaling up production in licensed areas of the operation. We expect to be in full production and to also have nationwide distribution for the recreational market in the months ahead.”

Emerald is currently delivering cannabis in Ontario, British Columbia, Yukon, and Newfoundland and Labrador, and has a signed sales agreement with Alberta Gaming, Liquor and Cannabis (AGLC) and is registered by the Saskatchewan Liquor and Gaming Authority (SLGA) to supply cannabis.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is licensed to cultivate in 1.03 million square feet of the first of it’s two 1.1 million square foot greenhouses. The capacity of each greenhouse is estimated to exceed 75,000 kg of cannabis annually. The initial facility has been scaling up production over the last four quarters and will be fully planted in April. Emerald’s Verdélite operation in Québec is completing the build out of its 88,000 square foot indoor cultivation facility and is scaling up production. Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol (CBD). Emerald has secured exclusive strategic partnerships for large scale extraction and softgel encapsulation, as well as for proprietary technology to enhance cannabinoid bioavailability. Its team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers.

Emerald is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:

Rob Hill, Chief Financial Officer

(800) 757 3536 Ext. # 5

Emerald Investor Relations

(800) 757 3536 Ext. #5

invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include projected job creation figures at our operating facilities; production and processing capacity of various facilities; expansion of facilities; and anticipated production costs.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

Source: Emerald Health Therapeutics Inc.

TORONTO, April 3, 2019 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that it has signed multi-channel distribution agreements for its Kuida® cosmeceutical brand with Fedco and Linio, two of the most prominent consumer distribution channels for wellness and beauty products in Colombia.  In combination with the initial product launch through Farmatodo and Farmalisto, it is anticipated that the Kuida® brand will now be made available in up to 78 retail locations and through the country’s leading online portal for beauty products. Initially focused on distribution in Colombia, these agreements create potential for the Company to further expand distribution across other Latin America jurisdictions.

• Retail distribution with Fedco, the first and most established specialized beauty retailer in Colombia, with 22 stores expanding reach to 50% of Colombia’s territory
• Online distribution secured with Colombian e-retailer Linio, controlled by Grupo SACI Falabella, the largest retailer in Latin America with approximately US$15 billion in revenue in 2017
• Increases Kuida® brand retail exposure to 78 store locations and approximately 600,000 monthly e-commerce visitors
• New agreements demonstrate continued first-mover advantage following successful initial Farmatodo product launch

Management Commentary

Alvaro Torres, CEO and a Director of Khiron, comments: “These agreements with Fedco and Linio further deliver on our market strategy for Kuida® and provide the flexibility to tap into cross-selling opportunities as consumers increasingly adopt CBD based cosmeceuticals into their skincare regimen. We look forward to working with some of the largest retailers in Colombia as the Kuida® brand increases its presence in the marketplace and is positioned for future growth.”

Cristina Acosta, Marketing Director of Fedco comments: “We are happy to announce this retail distribution agreement with Khiron for the Kuida® brand. Our company also seeks to provide consumers with the most innovative and unique line of product offerings and we believe the Kuida® brand aligns perfectly with this core objective. We also believe this arrangement represents an excellent union between two Colombian companies that will result in positive economic opportunity and development.” The agreement with Fedco gives Kuida® prominent store merchandising and point of sale display across 14 cities in Colombia.

Camila Gonzalez Manager of Beauty and Fashion Category of Linio comments: “We are pleased with this agreement with Khiron because of the potential that the Kuida® brand has in the Latin-American market. We have a strong presence in the region and look forward to introducing the brand and the category to our consumers.”

About Fedco

Fedco is one of the largest beauty retailers in Colombia with 40 years in the market, generating over 600,000 transactions per year.

About Linio

Linio is the leading online store in Latin America with more than 600,000 visits monthly, 20,000 Items dispatched monthly, and a strong presence in 6 countries within the region. Parent company Grupo SACI Falabella, a large retailer with presence in Chile, Peru, Colombia, Argentina, Brazil, Uruguay and Mexico.

About Kuida® 

Kuida®, the first consumer brand of Khiron’s wellness business unit, brings the benefits of cannabidol (CBD) to a comprehensive portfolio of skin and body care products for women. Kuida® was launched in Colombia in September 2018 through retail, wholesale and online channels and with a distribution agreement with Farmatodo, one of Colombia’s largest pharmacy chains with 56 stores.

About Khiron

Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/

To be added to the distribution list, please email khiron@kcsa.com with “Khiron” in the subject line.

CAUTIONARY NOTES

Market and Industry Data

This press release contains market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by  statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Forward-looking statements herein include, but are not limited to, statements regarding the anticipated benefits of the distribution agreements, including online and physical retail consumer exposure, and potential expansion into other jurisdictions, among others. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: cnaprawa@khiron.ca; Phil Carlson, KCSA Strategic Communications, 212-896-1233, E: khiron@kcsa.com; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: jpacker@khiron.ca

TORONTO, April 3, 2019 /CNW/ – SOL Global Investments Corp. (“SOL Global” or the “Company“) (CSE: SOL) (OTCQB: SOLCF) (Frankfurt: 9SB) is pleased to announce that 3 Boys Farms, LLC (“3 Boys Farm“), which owns and operates one of the fourteen medical marijuana treatment center licenses in Florida, has received approval from the State of Florida’s Department of Health, Office of Medical Marijuana Use (“OMMU“) to begin processing and dispensing cannabis products at its new state-of-the-art extraction and processing facility in Indiantown, Florida. SOL Global is in the process of acquiring 3 Boys Farms through its previously announced acquisition of CannCure Investments Inc. (“Canncure“) pursuant to a binding share purchase agreement. Closing of the acquisition is expected to occur within the next week and remains subject to a number of closing conditions including receipt of all necessary corporate approvals, however SOL Global has already been approved to acquire and own Canncure and 3 Boys Farms by the OMMU.

Accordingly, 3 Boys Farms has dispensed its first approved cannabis product – a 300mg low-THC cannabis vaporizer pen – to its first qualified patient in Florida. The OMMU has authorized 3 Boys Farms to dispense said vaporizer pen products via delivery to qualified patients throughout the state, and the first delivery to a qualified patient was made on April 1, 2019.

3 Boys Farms has also sought approval from the OMMU to begin dispensing its other premium cannabis flower products to Florida’s patients, including its “Cathy’s Choice” flower line. “Cathy’s Choice” flower was developed in part by (and is named in honor of) Parrish, Florida resident Catherine Jordan, the renowned medical cannabis activist who was diagnosed with Amyotrophic Lateral Sclerosis (ALS) in 1986 and became among the most dedicated and outspoken advocates both in Florida and throughout the country for patients wishing to access medical cannabis. 3 Boys Farms holds the exclusive right via a binding licensing agreement to cultivate and dispense “Cathy’s Choice” flower.

Concurrent with this announcement, SOL Global is pleased to announce that 3 Boys Farm’s brand new, state-of-the-art GMP-certified processing and extraction facility in Indiantown, Florida has commenced full operations. 3 Boys Farm’s processing facility is part of a newly designed 33-acre site in Indiantown that will also house a 50,000 square-foot greenhouse and a 64,000 square-foot indoor cultivation, processing, and manufacturing facility. The site is strategically located less than 90 miles from South Florida, which is poised to become one of the largest cannabis markets in the state. The commencement of operations in the new greenhouse or indoor cultivation, processing and manufacturing facility remains subject to the receipt of all required governmental approvals from the Florida Department of Health, Office of Medical Marijuana Use.

3 Boys Farm’s current approved cultivation facility in Ruskin, Florida produces approximately 350 pounds of dried cannabis flower product per month.

About SOL Global Investments Corp.

SOL Global is an international investment company with a focus on, but not limited to, cannabis and cannabis related companies in legal U.S. states, the hemp and CBD marketplaces and the emerging European cannabis and hemp marketplaces. Its strategic investments and partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami. It is this comprehensive approach that is positioning SOL Global as a future frontrunner in the United States’ medical cannabis industry.

Cautionary Statements
This press release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, but are not limited to: the Company’s ability to comply with all applicable governmental regulations in a highly regulated business; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use and adult-use marijuana industry; and regulatory or political change. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed on SEDAR and can be accessed at www.sedar.com.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

SOURCE SOL Global Investments Corp.

For further information: SOL Global Investments Corp.: Brady Cobb, CEO, Phone: (212) 729-9208, Email: info@solglobal.com; For media inquiries, please contact: Daniel Nussbaum, AMWPR, P: 212.542.3146, E: Daniel@amwpr.com

TORONTO, April 2, 2019 /CNW/ – 48North Cannabis Corp. (“48North” or the “Company”) (TSXV:NRTH) is pleased to announce that the Company has closed its previously announced “bought deal” short form prospectus offering of units (“Units”) of the Company (“Offering”) for total gross proceeds of approximately $28.75 million, which included the exercise of the over-allotment option granted to the Underwriters (defined below) in full. Pursuant to the Offering, 21,139,760 Units were sold at a price per Unit of $1.36 (“Issue Price”) for gross proceeds of $28,750,073.60. The Offering was completed by a syndicate of underwriters including Eight Capital, as sole bookrunner and lead underwriter, and Canaccord Genuity Corp. (“Underwriters”).

Each Unit was comprised of one common share of the Company (“Common Share”) and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $1.72, for a period of 60 months following the closing of the Offering. If the volume weighted average price of the Common Shares on the TSX Venture Exchange is equal to or greater than $3.30 for any 10 consecutive trading days, the Company may, within 10 days of the occurrence of such event, provide written notice to the holders of Warrants, supplemented by way of news release, of the acceleration of the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

As consideration for their services, the Underwriters received a cash commission equal to 6.0% of the gross proceeds of the Offering (excluding proceeds derived from certain purchasers on the Company’s president’s list, for which the cash commission was reduced to 3.0%). As additional consideration, the Company issued a total of 1,195,416 compensation options to the Underwriters. Each compensation option is exercisable into one Unit at the Issue Price until April 2, 2022.

As described in the Prospectus (defined herein), the Company, subject to applicable regulatory approvals, intends to use the proceeds to develop its indoor cannabis production facility located in Brantford, Ontario and its 100-acre outdoor farm in Brant County, Ontario, as well as for general corporate and other working capital purposes.

“48North is pleased to announce that it has closed its previously announced bought deal. 48North will use the proceeds of the Offering to execute on its business plan, namely developing its proposed 100-acre outdoor cultivation site in Brant County, and the distribution of next-generation cannabis products to consumers for retail sale in Canada come October 2019“, said Alison Gordon, co-CEO of 48North.

The Units were offered and sold by way of a short form prospectus dated March 26, 2019 (the “Prospectus”) filed in each of the provinces of Canada, excluding Quebec.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in the United States in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

About 48North

48North Cannabis Corp. (TSXV: NRTH) is a vertically integrated cannabis company focused on the health and wellness market through cultivation and extraction, as well as the creation of innovative, authentic brands for next-generation cannabis products. 48North is developing formulations and manufacturing capabilities for its own proprietary products, as well as positioning itself to contract manufacture similar products for third parties. 48North operates two indoor-licensed cannabis production sites in Ontario. 48North cultivates unique genetics at its wholly owned subsidiaries, DelShen Therapeutics Corp. (“DelShen”) and 2599760 Ontario Corp. dba Good & Green (“Good & Green”), both Licensed Producers under the Cannabis Act. In addition, subject to Health Canada approval, 48North expects to operate a 100-acre organic farm providing 48North with organic, sun-grown cannabis securing a significant first-mover advantage in the production of low-cost, next-generation, extract-based cannabis products. 48North has a growing portfolio of brands that include Latitude, a women’s cannabis platform (explorelatitude.com), Mother & Clone, a rapid-acting sublingual cannabis nanospray (momandclone.com) and Avitas, a single strain vaporizer cartridge (avitasgrown.com).

DISCLAIMER & READER ADVISORY

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could,” “intend,” “expect,” “believe,” “will,” “projected,” “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Forward-looking information in this news release includes statements relating to the business plan and future operations of the Company, including its application with Health Canada for a cultivation licence for its 100-acre outdoor grow property. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking information, including the possibility that the business plan described herein will not be completed, that 48North may not derive the expected benefits from such business plans, or that applicable regulatory approvals will be obtained to carry out the activities contemplated herein. The business of the Company is subject to a number of material risks and uncertainties. Please refer to the Company’s SEDAR filings for further details, including the risk factors in the annual information form of the Company dated March 12, 2019 and the Prospectus. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the Company being able to obtain the necessary corporate, regulatory and other third-party approvals, and  licensing and other risks associated with the Cannabis Act. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

SOURCE 48North Cannabis Co.

For further information: Alison Gordon, Co-Chief Executive Officer, (hello@48nrth.com); Connor Whitworth, Director of Corporate Affairs, (investor@48nrth.com)

Ottawa, Ontario, April 02, 2019 (GLOBE NEWSWIRE) — LiveWell Canada Inc. (“LiveWell” or the “Company“), (CSE: LVWL), is pleased to announce that on March 29, 2019, it closed the acquisition of all issued and outstanding common shares of privately held Acenzia Inc., an advanced developer and manufacturer of natural health products and dietary supplements based in Tecumseh, Ontario. Pursuant to the terms of the agreement dated December 14, 2018, LiveWell and Acenzia agreed to a total purchase consideration of $20 million which includes an $8 million earn-out payment upon the attainment of certain financial targets in calendar 2019.

The acquisition, announced on October 5, 2018, is a key part of LiveWell’s strategy to become a fully integrated global CBD life sciences company. LiveWell will leverage Acenzia’s state-of-the-art manufacturing capabilities and distribution networks within the supplements markets to deliver health and wellness products to targeted consumer markets.

“Acenzia is a great strategic fit. But a major factor in our acquisition is the company’s focus on science,” said David Rendimonti, President and CEO of LiveWell. “We are a research-driven organization, and Acenzia’s best-in-class, globally patented research model for developing and testing product efficacy in natural health products, and applying that to manufacturing the products, is simply revolutionary. No one else is doing this,” Mr. Rendimonti added.

Acenzia’s globally patented physiological research model will greatly advance the research being done on CBD and other cannabinoids for specific therapeutic uses.  CBD dosing is another key area of discovery the Company will explore through Acenzia’s research model, which involves the ethical testing of specially bred zebrafish.

Acenzia’s co-founder, Indrajit Sinha, is a peer-reviewed, world-class scientist specializing in immunology, and initially developed the in-vivo research model for oncology applications, to test efficacy of cancer drugs and metastasis. Dr. Sinha recognized the potential of applying the model to natural health products to produce better results and improve batch-to-batch efficacy in the manufacturing process.

“In a natural health product, there might be 50 ingredients on the label. With this model, we can test and evaluate the ingredients rapidly, and then standardize and validate the inputs to ensure batch-batch efficacy,” Dr. Sinha explained.

The new division of LiveWell has been manufacturing products such as powders, sports drinks, functional foods and other therapeutics for client-partners such as Iovate Health Sciences International and others since 2011.

In March, Acenzia  achieved GMP and GMP for Sport certifications by the NSF international standards body for the seventh consecutive year. It is one of a few Canadian manufacturers to attain this prestigious mark of quality, purity and safety controls. Acenzia’s 36,000-square-foot facility includes 20 pharmaceutical-grade clean rooms. It is also certified by Health Canada and is a USDA-Certified Organic Manufacturer and an FDA-registered facility.

Transaction Summary
The $20 million purchase consideration remains consistent with the terms of the definitive agreement as announced on December 19, 2018, with the shareholders accepting $2 million promissory notes and $18 million in common shares. The promissory notes carry a 10% annual interest rate and will mature on June 30, 2019.

In connection with this acquisition, LiveWell has issued 21,428,571 common shares at $0.84 each to the shareholders of Acenzia of which 9,523,808 common shares were held in escrow subject to achieving a minimum Adjusted EBITDA target for 2019 as defined in the definitive agreement.  In addition, a private lender of Acenzia Inc. elected to convert 50% of its $750,000 loan or $375,000 for  LiveWell common shares at a price of $0.84 each, for a total of 446,428 common shares.

A finder’s fee of $70,000 was paid in conjunction with the Transaction.

About LiveWell

LiveWell is an innovative Canadian company focused on advanced research of CBD and other cannabinoids. Through state-of-the-art cultivation and manufacturing, LiveWell aims to cost-effectively extract and refine large quantities of hemp-derived CBD, better enabling it to develop, market and distribute wholesale and consumer products.

For more information, visit livewellcorp.com

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements about the Company and its business. Often, but not always, forward-looking statements can be identified by the use of words such as “plan”, “continue”, “expect”, “schedule”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements (including negative variations) that certain events or conditions “may” or “will” occur. Such statements are based on the current expectations of management. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of unknown and known risk factors and uncertainties affecting the Company. Further, the Company cautions that this foregoing list of material factors is not exhaustive, and readers are encouraged to read all Risk Factors disclosed in the Company’s Management Discussion & Analysis dated October 26, 2018.

The forward-looking information contained in this press release represents expectations of the Company as of the date of this press release and accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Deborah Stokes
LiveWell Canada Inc.
819 576 3789
dstokes@livewellfoods.ca

Conrad Seguin
LiveWell Canada
cseguin@livewellfoods.ca

VANCOUVER, British Columbia, April 3, 2019 /PRNewswire/ — CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) has been advised by its tenant brand sales team that the Hempire and Evolution brands are now available in 40 retail locations, mostly along the coastal cities of Washington.

The flower is available in eight different strains across seven sizes with concentrates being made available in five different concentrates across 20 separate strains giving the retail locations over 100 SKUS to offer their consumers.

The Washington market for 2018, according to Statista.com, was a $534.06 Million market with RBC Capital Markets analyst Nik Modi writing: ‘The legal cannabis category [in the U.S.] is set to grow at a 17% CAGR over the next decade to as much as $47 billion in annual sales.’

Crop’s tenanted Washington facility has a major advantage with low cost electricity at $0.02 per kWh and greenhouse style growing, making it one of the most efficient growing operations available in the state of Washington for high quality product.

CROP CEO, Michael Yorke, stated: “Our tenant growing team and their sales team have made outstanding progress with product placement in 40 retail locations for both flower, oils and extracts. We continue to build out our brands in California and Nevada and our objective is, ultimately, to be in as many states as possible.”

About CROP

CROP is publicly listed company trading under symbol CROP.CSE. The company is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of Hemp CBD farms, and a growing portfolio of common share equity in upcoming listings within the cannabis space.

CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line and 16 Cannabis brands.

Disclaimer for Forward-Looking Information

Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Washington Project; the technological effects of Washington Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

The CSE has not reviewed, approved or disapproved the content of this press release.

Company Contact
Michael Yorke – CEO and Director 
E-mail: info@cropcorp.com 
Website: www.cropcorp.com
Phone: +1(604) 484-4206

SOURCE Crop Infrastructure Corp.

VAUGHAN, ON, April 2, 2019 /PRNewswire/ – CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX:TRST,NYSE: CTST) is pleased to announce that it has closed the first of its previously announced transactions to acquire 200 acres of outdoor cultivation land. The Company has purchased four parcels of land for cash, representing 81 acres of land, to advance its outdoor cannabis cultivation operation in British Columbia.

“We are very pleased to be executing on our plans to increase capacity through outdoor cultivation. Cannabis harvested from this new location will be used to produce the Company’s award-winning oil products as well as its future product innovations as Canadian regulations expand to include new product formats. The Company will continue to sell high quality dry flower from our Perpetual Harvest Greenhouses in Pelham, Ontario to medical and recreational consumers, and will use cannabis cultivated outdoors for its premium-priced extraction products at a fraction of the cost,” said Peter Aceto, Chief Executive Officer. “Subject to Health Canada approval, it is our plan to have plants in the ground and our first harvest from the 81 acres in 2019. Additional land is intended to be secured by the Company, which will bring outdoor cultivation to 200 acres, and will lead to total annualized production capacity of between 200,000kg and 300,000kg for the Company. Production from these additional lands are expected to come online in the third quarter of 2020, subject to regulatory approvals. We believe the transaction further demonstrates CannTrust’s low-cost cultivation leadership and is another example of CannTrust taking bold action to reach its vision of becoming a global leader in providing innovative cannabis products.”

CannTrust’s Outdoor Cultivation Capacity Continues to Grow

With the closing of this land acquisition, the Company has now secured 81 acres of land on which it will proceed to develop its outdoor cultivation capacity. CannTrust has commenced fencing of the property, installation of security systems and other infrastructure required for commercial production.

CannTrust expects to close a second transaction, which is currently under Letter of Intent, to secure additional land through long-term lease agreements in the near term. As previously announced, between the land acquisition announced today and the pending lease agreement, the Company expects to secure over 200 acres of total land for outdoor cultivation. Details of these transactions, including the location of the properties, will be disclosed upon satisfaction of customary closing conditions of the lease agreement.

Together these purchase and lease agreements are expected to add 100,000kg to 200,000kg of annualized production capacity in the third quarter of 2020, for an expected combined annualized production capacity, including the Company’s Perpetual Harvest Greenhouses in Pelham, Ontario, of between 200,000kg and 300,000kg, subject to receipt of Health Canada approvals.

About CannTrust

CannTrust is a federally regulated licensed producer of medical and recreational cannabis in Canada, and the 2018 Canadian Cannabis Awards “Top Licensed Producer of the Year”. Founded by pharmacists, CannTrust brings more than 40 years of pharmaceutical and healthcare experience to the medical cannabis industry and serves more than 68,000 medical patients with its dried, extract and capsule products. The Company operates its 450,000 sq. ft. Niagara Perpetual Harvest Facility in Pelham, Ontario, has been permitted to construct another 390,000 sq. ft. facility in Pelham, and prepares and packages its product portfolio at its 60,000 sq. ft. manufacturing centre of excellence in Vaughan, Ontario.

CannTrust is developing nanotechnology to develop new products in the medical, recreational, beauty, wellness and pet markets. The Company has established its international footprint through a strategic partnership with Cannatrek Ltd. in Australia and a joint venture with STENOCARE in Denmark. The Company has also partnered with Breakthru Beverage Group through Kindred Canada, for recreational distribution in Canada. CannTrust is committed to research and innovation through partnerships with McMaster University in Ontario and Gold Coast University in Australia, which were designed to contribute to the growing body of evidence-based research regarding the use and efficacy of cannabis.

For more information, please visit www.canntrust.ca.

Forward Looking Statements

This press release contains “forward-looking information” within the meaning of Canadian Securities laws and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other applicable United States safe harbor laws and such statements are based upon CannTrust’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as “believes”, “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.

The forward-looking information and statements in this news release are based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information and statements includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information and statements necessarily involve known and unknown risks, including, without limitation: risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States and elsewhere; the cannabis industry in Canada generally; and, the ability of CannTrust to implement its business strategies.

Any forward-looking information and statements speak only as of the date on which they are made, and, except as required by law, CannTrust does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for CannTrust to predict all such factors. When considering these forward-looking information and statements, readers should keep in mind the risk factors and other cautionary statements in CannTrust’s Annual Information Form dated March 28, 2019 (the “AIF“) and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com and filed as an exhibit CannTrust’s Form 40-F annual report under the United States Securities Exchange Act of 1934, as amended, with the United States Securities and Exchange Commission on EDGAR at www.sec.gov. The risk factors and other factors noted in the AIF could cause actual events or results to differ materially from those described in any forward-looking information or statements.

The TSX and NYSE do not accept responsibility for the adequacy or accuracy of this release.

Copyright © 2019 CannTrust Holdings Inc.

SOURCE CannTrust Holdings Inc.

Related Links

https://www.canntrust.ca/

TORONTO, April 2, 2019 /CNW/ – Flower One Holdings Inc. (“Flower One” or the “Company“) (CSE: FONE) (OTCQB: FLOOF) is pleased to announce a new long-term licensing agreement with The Medicine Cabinet, a high-end, boutique-style recreational cannabis brand that, through this partnership, will make its first foray into the United States market by way of Nevada. The addition of The Medicine Cabinet to Flower One’s growing portfolio of Brand Partners will allow the cannabis cultivator and producer to bring another product line to cannabis retailers, and therefore consumers, in Nevada.

“It’s our pleasure to announce Flower One’s latest brand partnership with The Medicine Cabinet. To be bringing this product portfolio to the United States for the very first time is a point of pride for Flower One,” said Ken Villazor, President and CEO of Flower One. “We’re excited to further diversify the brands and product we’re able to offer Nevada’s retailers and to continue establishing ourselves as a leader in the cannabis industry.”

“With 42 million tourists visiting Las Vegas every year, there couldn’t be a better American market for us to put The Medicine Cabinet products in front of – and we’re thrilled to be partnered with a recognizable producer like Flower One for fulfillment,” said a representative from The Medicine Cabinet. “After visiting the Flower One facility and getting to know the team’s executives and experienced growers, we were confident that this partnership would ensure our initial arrival in Nevada, and the United States in general, is a success. With Flower One’s up and coming cultivation and production capabilities, we’re at ease knowing that we’ll be able to continue delivering high quality, Ultra Premium Cannabis in and throughout our product and brands.”

Soon to be available in Nevada are The Medicine Cabinet’s Don Pablo Premium pre-rolls, a selection of Bomb Girl’s edibles and pre-roll Slims and Baby J’s, as well as a variety of Coffeeshop Classics dried flower.

About Flower One Holdings Inc.
Flower One is sharply focused on quickly becoming the leading cannabis cultivator, producer and innovator in the highly lucrative Nevada market. Flower One is rapidly converting its 455,000 square foot greenhouse and production facility, the largest in the State of Nevada, for the cultivation and production of high-quality cannabis at scale. It also owns and operates a 25,000 square foot indoor cultivation and production facility in North Las Vegas, with nine grow rooms, and owns the established NLV Organics consumer brand of cannabis products. Combined, the flagship greenhouse and production facility and the North Las Vegas facility provide Flower One with 480,000 square feet of capacity for cultivation and processing, production and high-volume packaging of dry flower, cannabis oils, concentrates and infused products. Flower One is fully licensed for medical and recreational marijuana cultivation and production in the state of Nevada and currently holds licensing agreements with their Brand Partners, Flyte Concentrates, Rapid-Dose Therapeutics’ Quick Strip, Old Pal, Palms, HUXTON, CannAmerica Brands, G Pen, and The Medicine Cabinet.

Flower One’s common shares are traded on the Canadian Securities Exchange under the symbol “FONE” and in the United States on the OTCQB under the symbol “FLOOF.” For more information visit: https://flowerone.com

About The Medicine Cabinet
The Medicine Cabinet seeks to provide a variety of high end, boutique-style recreational products and brands, including: Don Pablo’s signature line of hand rolled Premium Classics and Premium Exotics, Bomb Girl’s sleek selection of pre-rolled Baby J’s, and Slims, and for the connoisseur, Coffeeshop Classics, the finest in superior flavours and aromas. The Medicine Cabinet is dedicated to cultivating only the highest quality of Ultra Premium Cannabis delivered in the most innovative products and brands to medical and recreational users. For more information, visit https://themedicinecabinet.com

Cautionary Note Regarding Forward Looking Information

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Flower One’s public documents. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward- looking statements.

Forward-looking statements may include, without limitation, statements relating to the execution of the Company’s strategy and intent to quickly become the leading cannabis cultivator, producer and innovator in Nevada; the profitability of Flower One’s activities in Nevada; the number of tourists visiting Las Vegas every year; the scale and capacity of Flower One’s cultivation, processing and high-volume packaging facilities in Nevada; Flower One’s ability to expand its cannabis offerings in Nevada or to offer the most cutting-edge cannabis experience; Flower One’s ability to make The Medicine Cabinet’s product series available in Nevada or to offer a diversity of products; the term of the licensing agreement with the Medicine Cabinet; Medicine Cabinet’s ability to continue delivering high quality, Ultra Premium Cannabis in and throughout our product and brands; and the potential quality and effects of The Medicine Cabinet’s product series.

Although Flower One has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects that are engaged in activities currently considered illegal under United States federal law; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Flower One Holdings disclaims any intention or obligation to update or revise such information, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR THEIR REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Flower One Holdings Inc.

For further information: For inquiries please contact: Flower One Holdings Inc., Ken Villazor, President and CEO, 416.200.7641, kvillazor@flowerone.com; Flower One Investor relations inquiries: NATIONAL Capital Markets, 416.848.9835, ir@flowerone.com; Flower One media inquiries: Natalie Martin, 604.738.2220, flowerone@talkshopmedia.com

WINNIPEG, MB / TheNewswire / April 2, 2019 – DELTA 9 CANNABIS INC. (TSXV: NINE) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce the grand opening of its Delta 9 Cannabis Superstore in the Brandon Shoppers Mall in the City of Brandon, Manitoba. The Company is also reporting it has now surpassed 100,000 retail cannabis transactions since legalization of recreational-use cannabis last fall.

“With this newest store opening we’re extremely excited to be able to offer the citizens of Brandon a truly unique retail cannabis shopping experience” said John Arbuthnot, CEO. “Delta 9’s Cannabis Superstore concept combined with our focus on convenient and high traffic shopping destinations have been very successful as a part of our company’s overall vertical integration strategy.”

At approximately 4,500 square feet the newest Delta 9 Cannabis Superstore is one of the largest cannabis retail stores in the country, offering customers an open and modern shopping decor, highly trained staff and a wide range of product SKU’s including dried cannabis flower, cannabis oil, a full assortment of cannabis accessories, and a large customer education center providing customers with education programing for the adult recreational market.

The store is conveniently located in the Brandon Shoppers Mall at 1570-18th Street in Brandon. The Mall is a 367,000-square-foot enclosed regional shopping center located in Brandon, Manitoba. The mall features more than 90 retailers including Shoppers Drug Mart, Sobeys, Dollarama, Sport Chek, and Landmark Cinemas, offering a merchandise mix of retail, services, entertainment and restaurants.

Delta 9, through its partially-owned subsidiary, Delta 9 Lifestyle Cannabis Clinic Inc., successfully launched its first retail cannabis store in Winnipeg, Manitoba on October 17, 2018. The Company plans to open an additional retail outlet in Thompson, Manitoba in the near future, and has partnered with a Manitoba First Nation to open a fifth store. Additionally, the Company has prequalified for the Manitoba government’s request for proposals to open additional stores in smaller, rural communities. The Company plans to pursue additional expansion opportunities in cannabis retail across Canada over the course of the year.

For more information contact:

Investor & Media Contact:

Ian Chadsey VP Corporate Affairs

Mobile: 204-898-7722

E-mail: ian.chadsey@delta9.ca

About Delta 9 Cannabis Inc.

Delta 9 Cannabis is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the Cannabis Regulations (CR) and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE” and on the OTC under the symbol VRNDF. For more information, please visit delta9.ca.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) Delta 9’s expansion plans for its Winnipeg production facilities and for its network of retail stores; (ii) Delta 9’s capital raising plans; (iii) Delta 9’s production of cannabis; and (iv) costs for Delta 9’s expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including: (i) Delta 9’s ability to raise sufficient capital for its expansion plans; and (ii) Delta 9 obtaining all regulatory approvals, as well as all risk factors set forth in the annual information form of Delta 9 dated May 31, 2018 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

AgraFlora Organics International Inc. CSE: AGRA makes a $1,000,000.00 investment to support the Empower growth plan, as Empower closes over $2,900,000.00 in debenture and equity financing.

VANCOUVER, April 2, 2019 /CNW/ – EMPOWER CLINICS INC. (CSE: EPW) (Frankfurt 8EC) (“Empower” or the “Company“), a growth oriented and diversified medical cannabis company, is pleased to announce the closing of its non-brokered private placement of unsecured convertible debentures (the “Debentures“) in the aggregate principal amount of $799,500.00 and its non-brokered private placement of an aggregate of 21,115,000 units of the Company (each, a Unit“) at a price of $0.10 per Unit for gross proceeds of $2,115,000.00 for a total of $2,914,500.00 (together, the “Offerings“).

The proceeds of the Offerings are expected to be used by the Company for the completion of strategic acquisitions and for general working capital and corporate purposes.

“The strong support in our financing round demonstrates that shareholders and investors have faith in our ability to execute on initiatives, as we establish vertical integration, connecting patient efficacy in our clinics with a diverse CBD product strategy and the backing of the science of extraction, all driven by data and analysis.” stated Steven McAuley, Empower Chairman and CEO.

Derek Ivany, President and CEO of AgraFlora commented, “As interest in cannabidiol (CBD) continues to expand both amongst the medical community and with retail consumers alike, we are excited to be making this strategic investment into Empower as they embark on this next phase of their growth plan.  With the prospect of multiple near term revenue streams and a robust clinic and patient network the Company presents a compelling platform from which to build upon.  We have been further assessing corporate synergy with Empower and look forward to collaborating on new initiatives in short order.”

RECENT HIGHLIGHTS

• Intention to Launch CBD Extraction Facility The Company intends to open a fully functioning hemp-based CBD extraction facility in greater Portland, Oregon in Q2 2019, with the first extraction system expected to have the capacity to produce 6,000 kilograms of extracted product per year. Empower has entered into a non-binding term sheet with Aibeida LifeTech Ltd. (“Aibeida“), whereby Aibeida has agreed to: sell and license specialized extraction equipment to Empower; provide facility build-out and set-up services; complete licensing and permitting requirements; perform equipment set-up, testing and activation; and provide ongoing facility management and maintenance for the first Empower CBD extraction facility. Aibeida’s director and Chief Scientist, Dr. Shuang Xie, PhD, will oversee and manage the Empower CBD extraction facility, which is expected to provide Empower with vertical integration into the CBD supply chain, producing isolates, distillates and crude oil that have shown successful third party test results in Aibeida’s initial test facility.
• Proposed Acquisition of Sun Valley Clinics Empower has entered into a non-binding term sheet to acquire the business of Sun Valley Certification Clinics Holdings LLC (“Sun Valley“), including its interests in certain affiliates, by way of a share or asset acquisition, subject to due diligence and customary closing conditions. Sun Valley operates a network of professional medical cannabis and pain management practices, with five clinics in Arizona, one clinic in Las Vegas, a tele-medicine platform serving California, and a fully developed franchise business model for the domestic cannabis industry. The current Sun Valley clinic locations are as follows:

4218 W Dunlap Ave, Phoenix, AZ
12801 W Bell Rd #145, Surprise, AZ
4015 E Bell Rd #130, Phoenix, AZ
2011 E University Dr, Mesa, AZ
7074 E Speedway Blvd, Tucson, AZ
2550 S Rainbow Blvd, Las Vegas, NV

• Focus on CBD Product Sales Empower has commenced selling its proprietary line of CBD-based products called SOLLIEVO, through its network of company-owned clinics in the United States. Empower’s patient base and customers are expected to benefit from access to high margin derivative products, including CBD lotion, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet elixir hemp extract drops. Patients and customers will be able to access Empower’s home delivery and e-commerce platform.
• CBD Market Demand The passing in the United States of the US$867 billion Agriculture Improvement Act (the “Farm Bill“) has legalized hemp and hemp-based products. This has created an opportunity for the production and sale of a variety of CBD-based products that can provide genuine help and effective relief to millions of people suffering from a variety of qualifying conditions. Recent reports and studies indicate the approval of the Farm Bill could create a US$20 billion industry by 2022.
• Increased Patient Access With a rapidly expanding company-owned clinic network and significant expansion opportunity assuming the successful acquisition of the Sun Valley franchise model, Empower anticipates it will grow its total patient list substantially in the years ahead. This is expected to provide greater opportunity for treatment analysis using artificial intelligence (AI).
• Market Leading Technology Empower utilizes a market-leading patient electronic management and POS system that is HIPAA compliant and provides insight to patient care. The Company supports remote patients using its tele-medicine portal, enabling patients who are unable to come to a location to benefit from a doctor consultation.

The Debentures bear interest at the rate of 6.0% per annum and mature on April 2nd, 2020, being 12 months from the closing of the Offerings (the “Closing“). The Debentures are convertible, at the option of the Company or the holder, into units of the Company (each, a “Debenture Unit“) at a conversion price of $0.11 per Debenture Unit, with each Debenture Unit consisting of one common share in the capital of the Company (each, a “Share“) and one share purchase warrant (each, a “Warrant“), with each Warrant exercisable into one Share (each, a “Warrant Share“) at a price of $0.16 per Warrant Share for a period of two years following the Closing, provided that the Company will have the right to accelerate the expiry date of the Warrants in the event that the closing sale price of the Shares on the Canadian Securities Exchange (the “CSE“) (or such other stock exchange as the Shares are then principally traded) is greater than $0.40 per Share for a period of 10 consecutive trading days at any time after the issuance of the Warrants.

Each Unit is comprised of one Share and one Warrant, with each Warrant exercisable into one Warrant Share at an exercise price of $0.16 per Warrant Share for a period of two years following the Closing, provided that the Company will have the right to accelerate the expiry date of the Warrants in the event that the closing sale price of the Shares on the CSE (or such other stock exchange as the Shares are then principally traded) is greater than $0.40 per Share for a period of 10 consecutive trading days at any time after the issuance of the Warrants.

The Debentures and the Units, and the underlying Shares, Warrants and Warrant Shares (collectively, the “Securities“), are subject to restrictions on resale under applicable Canadian securities laws for a period of four months and one day from the closing of the Offerings. None of the Securities have been or will be registered under the United StatesSecurities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would require registration or otherwise be unlawful.

ABOUT EMPOWER

Empower is a leading owner/operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative uses of medical cannabis. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based product options in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.

ABOUT AGRAFLORA

AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Service Canada and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit: www.agraflora.com

For French inquiries: Remy Scalabrini, Maricom Inc., E: rs@maricom.ca, T: (888) 585-MARI

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the proposed acquisition of Sun Valley; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the expected location of the proposed CBD extraction facility; the effectiveness of the extraction technology; the size of the leased facility; the expected benefits for Empower’s patient base and customers; access to Empower’s home delivery and e-commerce platform; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that: the proposed acquisitions and partnerships, including the Sun Valley and Aibeida transactions, may not be completed on the terms expected or at all; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operation by Q2 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

For further information: Investors: Steve Low, Boom Capital Markets, steve@boomcapitalmarkets.com, 647-620-5101; For French inquiries: Remy Scalabrini, Maricom Inc., E: rs@maricom.ca, T: (888) 585-MARI; Investors: Steven McAuley, CEO, s.mcauley@empowerclinics.com, 604-789-2146

Related Links

www.adiraenergy.com

VANCOUVER, British Columbia, April 01, 2019 (GLOBE NEWSWIRE) — Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) today announced the sale of its wholly owned subsidiary BSPG Laboratories Ltd. (“BSPG”) to a U.K. based private equity group (“buyer”) for US$14,000,000 in cash installments.  As a part of the transaction, Isodiol has secured an off-take supply agreement with the buyer to ensure continued distribution of its Purodiol and Isodiolex products.

A first installment of US $5,000,000 was paid on March 29, 2019, a second installment of US$5,000,000 is due by June 26, 2019, a third installment of US$2,000,000 is due by September 26, 2019, and a final installment of US$2,000,000 shall be payable upon the expansion of BSPG’s production capacity into its newly leased 20,000+ sq. ft. laboratory facility that is expected to increase BSPG’s capacity by 8-10 times its current capacity.

“The sale of BSPG is bittersweet for us,” said Marcos Agramont, CEO of Isodiol.  “We are great believers in the future of API CBD for clinical applications and future pharmaceutical products.  Fortunately, this sale will provide us with the supply necessary to fulfill our Purodiol and Isodiolex production needs and clinical research projects at a below market cost, with the ability to scale in step with BSPG’s expansion, but without having to incur dilution from raising the cash necessary for the expansion.  In effect, Isodiol will see a return of the cash committed to acquire BSPG, while retaining the benefits it sought in the acquisition.”

Isodiol’s board of directors also has concluded its recent efforts to eliminate certain costly long-term contracts and other liabilities from its balance sheet and future cash flow obligations totalling approximately US$11,809,539 in exchange for the new issuance of 6,587,170 shares at an average weighted price of CAN$1.89 per share.

“The board of directors is pleased to be entering Isodiol’s new fiscal year commencing April 1, 2019 with a cleaner slate and focused vision,” said Agramont.

Follow Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol.

About Isodiol International Inc.

Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. The Company received approval for its CBD as an Active Pharmaceutical Ingredient (API) for use in Finished Pharmaceutical Products (FPPs), as was announced on April 26, 2018.  Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe through the proliferation of its various brands, including the recently acquired CBD Naturals® portfolio of brands and proprietary technologies.

ON BEHALF OF THE BOARD

Marcos Agramont, CEO & Director

INVESTOR RELATIONS:

Ir@isodiol.com
604-409-4409

MEDIA CONTACT:

Christopher Hussey
media@isodiol.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, proposed arrangement with creditors, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

TORONTO, April 2, 2019 /PRNewswire/ – SOL Global Investments Corp. (“SOL Global” or the “Company“) (CSE: SOL) (OTCQB: SOLCF) (Frankfurt: 9SB) is pleased to announce its latest strategic investment, a significant position in premium hemp company Sacred Hemp (“Sacred“).

SOL Global has acquired a 10.3 percent stake in Sacred, the Chicago, Illinois-based manufacturer of premium hempseed oil-infused products including pain relief balms and oils, feminine products, massage oils, salt soaks, and personal lubricants.

SOL Global will assign its position in Sacred to its hemp/CBD-focused international subsidiary, Heavenly Rx.

Sacred’s product line includes its bestselling all-natural pain relief balms and lotions, made from a combination of natural hempseed oil extracts, essential oils, and menthol. Sacred’s Therapeutic Massage Oil is designed to rejuvenate even the most sensitive skin types and can help to reduce muscle inflammation and relieve muscle aches and pains. Sacred also offers four different varieties of salt soaks, including its Acai Berry Soak and its Dead Sea Salt Soak, as well as two varieties of natural hemp oil-infused personal lubricant, designed to enhance intimacy without irritants or harsh chemicals. Their female specific products include a PMS Pain Balm as well as an all-natural feminine wash.

Hemp seeds are rich in protein, polyunsaturated fatty acids, omega 6, omega 3 and insoluble fiber. They are a good source of tocopherols, or Vitamin E antioxidants, and packed with minerals such as potassium, magnesium, iron, zinc, calcium, and phosphorus. In contrast with CBD oil, hempseed oil extracts are 100% THC-free.

“Sacred Hemp’s wide range of hemp-derived products, representing numerous product categories across the cosmetics and bath and body space, is the perfect addition to Heavenly Rx’s substantial portfolio of hemp and CBD companies,” said Andy DeFrancesco, Chief Investment Officer of SOL Global. “We couldn’t be more excited to support Sacred Hemp and look forward to continued growth and innovation from its expert management team and dedicated staff.”

“SOL Global’s investment will help Sacred pursue Food and Drug Administration approval for its hemp seed oil-derived pain relief balms and lotions, with the aim of becoming among the first hemp companies in the United States to receive FDA approval,” said Sacred Hemp CEO Silvia Orizaba. “SOL’s investment will also help our company fortify and expand our existing product lines, as well as ramp up our consumer outreach efforts.”

SOL Global will review its investment in Sacred on a continuing basis and reserves the right to take any action with respect to its investment it deems appropriate, including, but not limited to, purchasing additional shares of Sacred, selling some or all of its shares of Sacred, or otherwise modifying its investment strategy with regard to Sacred.

About SOL Global Investments Corp.

SOL Global is an international investment company with a focus on, but not limited to, cannabis and cannabis related companies in legal U.S. states, the hemp and CBD marketplaces and the emerging European cannabis and hemp marketplaces. Its strategic investments and partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami. It is this comprehensive approach that is positioning SOL Global as a future frontrunner in the United States’ medical cannabis industry.

About Sacred Hemp

Sacred was founded on the belief that everyone should have access to natural, high quality products when it comes to caring for your body. Our products, including Pain Balm and Pain Relief Lotion, are 100% pure with no rich nutrients ever taken away. Each product is created with essential oils and hemp oil, offering healing effects. We’ve invested years in developing our products. Since the beginning, Sacred has been built on our two core values: purity of product and customer experience. Our belief in the highest quality possible is what differentiates our hemp oil products from similar THC-free products on the market. Our unique selection of ingredients creates natural products that you will love and are conveniently delivered right to your doorstep.

Cautionary Statements
This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, but are not limited to: the Company’s ability to comply with all applicable governmental regulations in a highly regulated business; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use and adult-use marijuana industry; and regulatory or political change. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed on SEDAR and can be accessed at www.sedar.com.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

The securities referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (“U.S. Securities Act“), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent such registration or an applicable exemption from the registration requirements of the U.S. Securities Act.  This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities.

SOURCE SOL Global Investments Corp.

Vancouver, April 02, 2019 (GLOBE NEWSWIRE) — Vancouver (April 2, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is pleased to announce its Evolve cannabis products will be available for purchase in California for the first time, after receiving final approval by the State of California.

NanoSphere’s Evolve Formula NanoSerum is expected to hit store shelves in the Los Angeles area by April 8th.

NanoSerum is a transdermal serum that immediately penetrates the skin to deliver direct-focused relief from pain, inflammation, and anxiety. The serum is able to easily pass through the skin due to NanoSphere’s patented nanoparticle technology.

The Evolve Formulas serum will begin shipping to retail outlets next week, said NanoSphere President David Sutton. “This is another major step for our Evolve Formulas line of cannabis products, as we are now moving into the largest legal cannabis market in the world,” Sutton said.

“We have had a great response to our NanoSerum in Colorado, and now this revolutionary product will be available to the people of California for the first time.”

The NanoSerum is produced and distributed in California by Vertical, one of the first and largest vertically integrated companies in the legal US medical cannabis industry. (vertcos.com) Vertical operates cannabis growing and extract operations, but also features world-class capabilities in product development, co-packing, branding, marketing, distribution and legal compliance.

“Vertical has been a great partner for our expansion into the California market,” said NanoSphere CEO Robert Sutton. “They have deep experience in marketing, distribution and regulatory from their past experience in the alcohol industry, and the same commitment to excellence has been applied to the cannabis industry.”

Vertical President J. Smoke Wallin said the approval of NanoSphere’s technology marks a new turning point in the cannabis industry. “Our team is dedicated to building out the industry’s leading sales and distribution platform in multiple markets, and a big part of that is bringing our customers the most advanced products for both the medical and recreational markets,” Wallin said. “We couldn’t be more excited to bring NanoSphere’s cutting edge solution Evolve to our licensed retailers and medical dispensaries in California.”

NanoSphere is preparing a second line of products to register for sale in the California and Colorado recreational cannabis markets. The Evolve Formulas NanoGel is produced by encapsulating a full spectrum of cannabinoids and terpenes in smart lipid nanoparticles, which are transported through the mucous membrane and into the bloodstream, activating target receptors in the brain within minutes.

Evolve Formulas NanoGel provides a faster onset, precise dosing, higher bioavailability, and a similar effect to smoking or vaping cannabis, but without the potential harm to the lungs.

Analysis by Cowen & Co. predicts the cannabis industry in the United States is expected to grow to $50 billion by 2026, with California accounting for about $25 billion of that market, according to a report by Cannabis Financial Network (CFN: https://www.prnewswire.com/news-releases/california-cannabis-market-expected-to-reach-51-billion-market-value-685917412.html)

On behalf of the Board

David Sutton, President and COO

720.845.1466

dsutton@nanospherehealth.com

Media Contact:

Gary Symons

Mobile: 250.300.9352

E-mail: gsymons@nanospherehealth.com

About NanoSphere

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world’s first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.

About Vertical

Vertical is a leading vertically-integrated multi-state operator and brand and distribution company in the medical and adult-use cannabis and Hemp-based CBD industries. With have operations in AZ, KY, and CA, combined with strategic partnerships in OH and additional markets which position it well to take advantage of the legalization and normalization of cannabis globally. Vertical is led by an executive team of entrepreneurs and business leaders from the alcohol beverage, agriculture, CPG, distribution, entertainment, food, healthcare, and medical industries.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Without limitation, these include assumptions, risks and uncertainties inherent in completing sub-licensing arrangements in the United States, Canada and abroad, product demand, production, competition and government regulation of the Cannabis industry, any and all of which may have an adverse effect on the Company’s expansion plans, sales, revenues and its financial results and condition.  Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

Attachment

• Lifestyle 4

Gary Symons
Nanosphere Health Sciences
2503009352
gsymons@nanospherehealth.com

Released April 2, 2019

Global cannabis sales are projected to grow by 38% to US$16.9 billion from 2018 to 2019. This rapid growth is creating demand from global investors for exposure to this nascent, but fast maturing industry. Nowhere is this more evident than in Latin America, where there are also thriving cannabis industries in countries such as Colombia and Uruguay. Citing this demand, The Arcview Group and Muisca Capital Group, will convene leading cannabis companies and investors from Latin America and around the world for the inaugural “Cannabiz Latino Hub – Impact Investment Summit”. The event will take place in Bogotá, Colombia on May 2nd at the 5-star Hotel Tequendama.

This private invite-only summit has been designed specifically for Latin American HNWIs, family offices, institutional investors, and fund managers to learn the intricacies of this industry and engage with investment opportunities in the global medicinal and recreational legal cannabis industry.

In addition to connecting Latin American investors with investment opportunities, this summit will also provide a unique platform for leading Latin American cannabis entrepreneurs to pitch and raise capital from international investors who are seeking to deploy capital into Latin America’s most promising cannabis start-ups and established companies.

Leading cannabis executives, thought leaders, and investment experts from around the world will be in attendance. Keynote, panel discussions, and investment pitches will cover Cannabis and Latin America, The Cannabis Value Chain, Market Insights, Direct Investment Opportunities, Export Strategies, Fund Investment Opportunities, Understanding and Analyzing the Public Markets, Capital Market Financing Strategies, Risks and Regulations, World Cannabis Policy and more.

Troy Dayton, CEO of The Arcview Group adds: “The global cannabis market is exploding, and Latin America is very much a part of the story. From the thriving export industry in Colombia to the legalization pioneer in Uruguay, Latin American investors and operators will play important roles in the global cannabis industry for years to come. In Colombia, for example, some expect the industry to eventually be bigger than the coffee, flower and banana industries together. The positive socio-economic impact that the legal cannabis industry is bringing to Latin America is undeniable and we are excited to help advance it by connecting global capital with opportunities in Latin America.”

Carol Ortega, Founding and Managing Director at Muisca Capital Group adds “With a population of more than 600 million inhabitants, the Latin American legal cannabis market is expected to be worth USD$13 billion by 2028. This is an emerging industry that was a source of conflict and war but has now become a unique opportunity to be a generator of wealth, diversity and inclusion in our communities. What’s missing, however, is a vibrant venture capital community to help propel Latin American cannabis companies to the next level and compete internationally. That is why we are so proud to pioneer the Latin American cannabis venture capital scene and provide these emerging companies with opportunities for growth capital. And there is no better place than to start then in Colombia, a country with a legal cannabis market that has attracted more than USD$220MM in foreign investment up to date, and where legalization of cannabis means peace and inclusion”

About The Arcview Group Founded in 2010, The Arcview Group is responsible for a number of groundbreaking ventures in the cannabis industry. The Arcview Investor Network has helped more than 1,200 investors place $200 million+ behind 190 companies. Arcview Market Research has published over 20 reports analyzing and forecasting the rapidly evolving cannabis space, and the flagship annual report, The State of Legal Marijuana Markets, has become the industry standard for market analysis and data in the sector. In 2015 Arcview became a partner in Canopy, the first seed-stage mentor-driven business accelerator. Arcview is also co-founder of Cannasure Insurance Services, the leading provider of business insurance to the cannabis industry. The Arcview Venture Fund is focused on providing growth and expansion capital to best-of-breed cannabis companies. Forbes Magazine recently named Arcview among the top 5 financial firms in the cannabis sector. Learn more at arcviewgroup.com.

About Muisca Capital Group Headquartered in California USA, Muisca Capital is the first Latino investment management firm supporting initiatives in the legal cannabis industry, through a combination of events, acquisitions, business incubation and venture capital. Our target is to build a portfolio of leading Latin American companies that will shape premium cannabis brands worldwide. Muisca Capital Group has created a financial vehicle valued at USD$70MM in order to mobilize investment in LATAM. Muisca Capital has chosen to start its operation in LATAM through the Colombian cannabis market given its maturity and leadership in the region. The firm expects to close its USD$9MM seed capital round next May 2nd at Cannabiz Latino HUB and will start deploying capital soon thereafter to leading companies in Colombia.